First author [Ref.] | Population | RC-time s | Coefficient of variation % | |
All patients | Subgroups | |||
Lankhaar [8] | NT, CTEPH, iPAH | 0.75# | ||
NT 0.79±0.31# | 39 | |||
CTEPH 0.74±0.37# | 50 | |||
iPAH 0.69±0.22# | 32 | |||
0.48±0.17¶ | 35 | |||
Lankhaar [9] | PAH and CTEPH | 0.61±0.15 | N/A | 25 |
Tedford [22] | Suspected or | 0.48±0.17 | 35 | |
documented PH | ILD 0.48±0.16 | 33 | ||
PAWP ≤10 mmHg 0.43±0.15 | 35 | |||
PAWP ≥20 mmHg 0.28±0.12 | 43 | |||
Dupont [23] | Heart failure | 0.35 | PAWP ≤17 mmHg 0.43 | |
PAWP >17 mmHg 0.30 | ||||
MacKenzie Ross [16] | PAH and CTEPH | iPAH 0.63±0.14 | 22 | |
Distal CTEPH 0.55±0.12 | 22 | |||
CTEPH pre-PEA 0.49±0.11 | 22 | |||
CTEPH post-PEA 0.38±0.11 | 29 | |||
Skoro-Sajer [19] | CTEPH | Pre-PEA 0.72±0.71 | 99 | |
Early post-PEA 0.60±0.30 | 50 | |||
1-year post-PEA 0.59±0.34 | 58 | |||
Tedford [26] | With and without PH | mPAP <25 mmHg 0.36 (0.29–0.47) | ||
mPAP ≥25 mmHg 0.53 (0.45–0.63) | ||||
Pellegrini [24] | CHF patients due to sLVD | 0.30±0.20 | 67 | |
with and without PH | PAWP ≥15 mmHg 0.28±0.22 | 79 | ||
PAWP <15 mmHg 0.34±0.14 | 41 | |||
Dragu [25] | CHF patients with no PH, | 0.25 | PAWP ≥20 mmHg 0.20 | |
passive PH and reactive PH | PAWP <20 mmHg 0.33 | |||
Ruiz-Cano [20] | PAH and CTEPH | PAH 0.66±0.23 | 35 | |
CTEPH 0.53±0.18 | 34 | |||
Newman [21] | PAH patients | Pre-NO 0.90±0.12 | 13 | |
Post-NO 0.78±0.22 | 28 |
Data are presented as mean, mean±sd or mean (range). RC-time: time constant of the monoexponential pulmonary artery pressure decay; PH: pulmonary hypertension (mean pulmonary artery pressure (mPAP) ≥25 mmHg); PVR: pulmonary vascular resistance calculated with zero-flow pressure (Pzf)=pulmonary artery occlusion/wedge pressure (except [8] where Pzf=0); SV/Papp: stroke volume/pulmonary arterial pulse pressure; NT: normotensive subjects with mPAP <25 mmHg; CTEPH: chronic thromboembolic pulmonary hypertension; iPAH: idiopathic pulmonary arterial hypertension; N/A: not applicable; ILD: interstitial lung disease; PAWP: pulmonary arterial wedge pressure; PEA: pulmonary thromboendarterectomy; mPAP: mean pulmonary artery pressure; CHF: congestive heart failure; sLVD: systolic left ventricular dysfunction; PAH: pulmonary arterial hypertension; NO: nitric oxide; The total arterial compliance was empirically estimated by using the SV/PApp (except [8], using either the energy balance method (#) or the pulse pressure method (¶)). Coefficient of variation=100×sd/mean.